Glucokinase Maturity-Onset Diabetes of the Young with Concurrent Islet Autoimmunity in a Child With Mild Stable Hyperglycemia: A Case Report
AACE Endocrinology and Diabetes · 2026-07
DOI: 10.1016/j.aed.2026.07.011 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-07. Verfasst von Supratik Bhattacharyya. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes in childhood is increasingly recognized as a heterogeneous condition that includes autoimmune, type 2, and monogenic forms. Glucokinase maturity-onset diabetes of the young (GCK-MODY) typically causes mild stable fasting hyperglycemia and is usually managed without pharmacologic therapy, whereas autoimmune type 1 diabetes is characterized by immune-mediated beta-cell injury that may progress through presymptomatic stages before overt hyperglycemia. When these features coexist, diagnostic classification and longitudinal follow-up become challenging. Case Presentation We report a 7-year-11-month-old boy evaluated for mild persistent hyperglycemia. Fasting plasma glucose ranged from 107–111 mg/dL, HbA1c from 6.01–6.20%, andoral glucose tolerance testing showed fasting plasma glucose of 109 mg/dL and 2-hour plasma glucose of 127 mg/dL. Fasting C-peptide was preserved at 1.63 ng/mL. Islet autoantibody testing demonstrated strongly positive glutamic acid decarboxylase 65 antibody (257.5 IU/mL) and positive zinc transporter 8 antibody (20.61 U/mL), while insulinoma-associated antigen-2 antibody was negative. Genetic testing identified a heterozygous likely pathogenic GCK variant, c.469G>A (p.Glu157Lys), consistent with GCK-MODY. Continuous glucose monitoring showed mean glucose of 120 mg/dL, glucose management indicator of 6.2%, time in range of 98%, and coefficient of variation of 17.7%.
Discussion
The child's mild stable fasting hyperglycemia, non-diabetic 2-hour oral glucose tolerance test value, preserved C-peptide, and low-variability continuous glucose monitoring profile were compatible with GCK-MODY. However, positive glutamic acid decarboxylase 65 and zinc transporter 8 antibodies indicated concurrent islet autoimmunity with potential future progression toward autoimmune type 1 diabetes. Because GCK-MODY itself can explain mild dysglycemia, the child should not be automatically classified as having stage 2 type 1 diabetes without evidence of progression beyond the expected GCK-MODY phenotype.
Conclusion
This case illustrates that positive islet autoantibodies do not exclude monogenic diabetes. In children with mild stable fasting hyperglycemia, preserved C-peptide secretion, and non-diabetic oral glucose tolerance test values, genetic testing remains important for accurate phenotypic classification. When GCK-MODY coexists with islet autoimmunity, longitudinal metabolic surveillance is required to detect progression beyond the expected GCK-MODY phenotype.
Zitieren
APA
Bhattacharyya, S. (2026). Glucokinase Maturity-Onset Diabetes of the Young with Concurrent Islet Autoimmunity in a Child With Mild Stable Hyperglycemia: A Case Report. AACE Endocrinology and Diabetes. https://doi.org/10.1016/j.aed.2026.07.011
Vancouver
Bhattacharyya S. Glucokinase Maturity-Onset Diabetes of the Young with Concurrent Islet Autoimmunity in a Child With Mild Stable Hyperglycemia: A Case Report. AACE Endocrinology and Diabetes. 2026. doi:10.1016/j.aed.2026.07.011
BibTeX
@article{Bhattacharyya2026,
author = {Bhattacharyya, Supratik},
title = {Glucokinase Maturity-Onset Diabetes of the Young with Concurrent Islet Autoimmunity in a Child With Mild Stable Hyperglycemia: A Case Report},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
doi = {10.1016/j.aed.2026.07.011}
}
EUVIMED